Quent Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$194K Sell
312
-54
-15% -$36.8K 0.01% 420
2026
Q1
$282K Sell
366
-112
-23% -$85.7K 0.02% 305
2025
Q4
$369K Buy
478
+38
+9% +$25.8K 0.03% 267
2025
Q3
$248K Buy
440
+2
+0.5% +$1.13K 0.02% 245
2025
Q2
$230K Buy
438
+39
+10% +$21.8K 0.02% 249
2025
Q1
$253K Sell
399
-22
-5% -$15.1K 0.03% 215
2024
Q4
$300K Buy
421
+2
+0.5% +$1.68K 0.03% 195
2024
Q3
$440K Buy
419
+8
+2% +$8.9K 0.04% 197
2024
Q2
$432K Buy
411
+21
+5% +$20.4K 0.05% 185
2024
Q1
$375K Buy
390
+19
+5% +$18.1K 0.04% 212
2023
Q4
$326K Buy
371
+14
+4% +$11.5K 0.04% 216
2023
Q3
$294K Buy
357
+24
+7% +$18.9K 0.05% 215
2023
Q2
$239K Buy
333
+7
+2% +$5.4K 0.04% 244
2023
Q1
$268K Buy
326
+3
+0.9% +$2.26K 0.05% 224
2022
Q4
$233K Buy
323
+15
+5% +$11.1K 0.04% 237
2022
Q3
$212K Buy
308
+4
+1% +$2.52K 0.04% 238
2022
Q2
$180K Sell
304
-17
-5% -$11.1K 0.04% 248
2022
Q1
$224K Sell
321
-922
-74% -$583K 0.04% 255
2021
Q4
$785K Buy
+1,243
New +$764K 0.17% 104

Other funds holding REGN

Quent Capital's REGN Position: Q2 2026 in Review

Quent Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 15% in Q2 2026, selling an estimated $36.8K and leaving 312 shares worth $194K. The position accounts for 0.01% of the portfolio, ranked #420.

Quent Capital first reported a position in REGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $785K in Q4 2021. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Quent Capital held 312 shares of Regeneron Pharmaceuticals worth $194K as of Q2 2026.
  • Quent Capital sold 54 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $36.8K.
  • Regeneron Pharmaceuticals made up 0.01% of Quent Capital's portfolio in Q2 2026, its #420 holding.
  • Quent Capital first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Quent Capital's Regeneron Pharmaceuticals position peaked at $785K in Q4 2021.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.